SpringWorks Therapeutics(SWTX) - 2020 Q3 - Quarterly Report

Financial Performance - The net loss for the three months ended September 30, 2020, was $21.7 million, an increase of 29% from a net loss of $16.8 million in the prior year[91]. - The net loss for the nine months ended September 30, 2020, was $56.8 million, compared to a net loss of $42.1 million for the same period in 2019, reflecting a 35% increase in losses[107]. - The accumulated deficit increased to $129.9 million as of September 30, 2020, up from $73.0 million at the end of 2019[107]. - Other income decreased by 49% to $1.2 million for the nine months ended September 30, 2020, down from $2.3 million in the same period of 2019[105]. Expenses - Research and development expenses increased by $3.2 million to $13.9 million for the three months ended September 30, 2020, representing a 29.6% increase compared to $10.7 million for the same period in 2019[92]. - General and administrative expenses rose by $3.1 million to $7.7 million for the three months ended September 30, 2020, a 67% increase from $4.6 million in the prior year[91]. - Total operating expenses for the three months ended September 30, 2020, were $21.6 million, up 41% from $15.3 million in the same period of 2019[91]. - Research and development expenses increased by $6.2 million to $36.6 million for the nine months ended September 30, 2020, representing a 20.5% increase compared to the same period in 2019[100]. - General and administrative expenses rose to $20.9 million for the nine months ended September 30, 2020, up from $11.5 million in the same period of 2019, marking an increase of 82%[103]. - Net cash used in operating activities was $47.3 million for the nine months ended September 30, 2020, compared to $31.4 million for the same period in 2019[110]. - Net cash used in investing activities surged to $196.1 million for the nine months ended September 30, 2020, compared to $4.1 million in the same period of 2019[111]. Cash and Liquidity - The company had a cash, cash equivalents, and marketable securities balance of $276.8 million as of September 30, 2020, which is expected to support operating expenses[81]. - The company had cash, cash equivalents, and marketable securities totaling $276.8 million as of September 30, 2020, compared to $327.7 million as of December 31, 2019[129]. - The company reported no outstanding debt as of September 30, 2020, indicating a strong liquidity position[129]. - The company anticipates needing additional funds for operational needs and capital requirements for clinical trials and research and development expenditures[115]. Investments and Collaborations - The company entered into multiple collaboration agreements with industry leaders, including a $35 million upfront payment from Jazz Pharmaceuticals for the FAAH inhibitor program[72]. - The company is focused on expanding its portfolio through licensing additional programs with strong biological rationales and validated mechanisms of action[79]. - The company is advancing two potentially registrational clinical trials: the DeFi trial for nirogacestat and the ReNeu trial for mirdametinib[86]. - The company expects research and development expenses to increase substantially as product candidates advance into later stages of development[86]. Market and Economic Conditions - Historical fluctuations in interest rates have not significantly impacted the company's financial results, and an immediate one percentage point change in interest rates would not materially affect the fair market value of cash equivalents[129]. - The company intends to maintain its portfolio of cash equivalents and marketable securities in high-quality, highly liquid investments to minimize future risks[129]. - The CARES Act, enacted on March 27, 2020, is not expected to materially impact the company's financial results or liquidity[128]. - The company does not believe that inflation, interest rate changes, or exchange rate fluctuations have significantly impacted its results of operations for the periods presented[129]. - The company will continue to monitor the impact of the CARES Act and similar legislation on its business and financial results[128]. - The company has relied on exemptions under the JOBS Act, including delaying compliance with certain accounting standards[126].